Rachel Tyndale
#99,969
Most Influential Person Now
Pharmacogenomics researcher
Rachel Tyndale's AcademicInfluence.com Rankings
Rachel Tyndalemedical Degrees
Medical
#1843
World Rank
#2221
Historical Rank
Pharmacology
#215
World Rank
#255
Historical Rank
Rachel Tyndalebiology Degrees
Biology
#7553
World Rank
#10493
Historical Rank
Computational Biology
#160
World Rank
#161
Historical Rank
Download Badge
Medical Biology
Why Is Rachel Tyndale Influential?
(Suggest an Edit or Addition)According to Wikipedia, Rachel Fynvola Tyndale is a Canadian pharmacogeneticist. She is a Professor in the Departments of Psychiatry, and Pharmacology and Toxicology at the University of Toronto and a Canada Research Chair in Pharmacogenomics. Tyndale is also the Senior Scientist and Head of Pharmacogenetics in the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health .
Rachel Tyndale's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Guidelines on nicotine dose selection for in vivo research (2007) (747)
- A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. (1997) (469)
- Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. (1989) (461)
- Nicotine metabolism defect reduces smoking (1998) (434)
- Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity (2004) (390)
- Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes (2017) (353)
- Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process (2014) (346)
- Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. (2004) (325)
- Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation (2006) (280)
- Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence (2005) (262)
- Nicotine-dependence symptoms are associated with smoking frequency in adolescents. (2003) (248)
- Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. (2000) (246)
- Inhibition of cytochromes P450 by antifungal imidazole derivatives. (2002) (232)
- Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. (2015) (222)
- Genetics of alcohol and tobacco use in humans (2003) (221)
- Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study (2009) (215)
- Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain (2003) (214)
- CYP2A6 genotype and the metabolism and disposition kinetics of nicotine (2006) (214)
- The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. (1990) (207)
- Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. (2011) (207)
- Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy (2006) (190)
- Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo‐controlled Trial of Bupropion (2008) (183)
- Drug-metabolizing cytochrome P450s in the brain. (2002) (170)
- Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. (2011) (170)
- Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking (2000) (165)
- Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. (2001) (161)
- The Role of CYP2A6 in the Emergence of Nicotine Dependence in Adolescents (2007) (160)
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. (1991) (149)
- Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics (2002) (145)
- Nicotinic acetylcholine receptor β2 subunit gene implicated in a systems-based candidate gene study of smoking cessation (2008) (141)
- An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. (2002) (140)
- Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. (1997) (140)
- Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. (2001) (140)
- Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations (2000) (138)
- CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial (2007) (134)
- The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics (2004) (133)
- Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers (2004) (133)
- Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes (2013) (132)
- Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics (2003) (130)
- Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior (2002) (129)
- Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates (2006) (128)
- Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. (1991) (127)
- Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes (2009) (125)
- CYP2A6 genetic variation and potential consequences. (2002) (124)
- Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. (2000) (123)
- Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. (2007) (121)
- Overview of the pharmacogenomics of cigarette smoking (2007) (120)
- Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures (2000) (119)
- Cytochrome P450-mediated drug metabolism in the brain. (2013) (117)
- Evidence of Association between Smoking and α7 Nicotinic Receptor Subunit Gene in Schizophrenia Patients (2004) (115)
- Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. (2004) (113)
- Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended‐Duration Transdermal Nicotine Therapy (2010) (111)
- A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus (1993) (108)
- NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. (1998) (107)
- Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). (1991) (107)
- Intercellular Calcium Waves in Neurons (1996) (105)
- Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level (2011) (105)
- Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicators. (2002) (98)
- Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. (1998) (97)
- A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism (2015) (97)
- Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers (2014) (96)
- An association of CYP2A6 genotype and smoking topography. (2007) (96)
- Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers (2012) (95)
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy (2019) (95)
- The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in caucasians (2007) (94)
- Nicotinic acetylcholine receptor variation and response to smoking cessation therapies (2013) (93)
- Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence (2005) (93)
- Characterization and Comparison of Nicotine and Cotinine Metabolism in Vitro and in Vivo in DBA/2 and C57BL/6 Mice (2007) (93)
- Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. (2001) (91)
- Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age (2011) (89)
- Nicotine physical dependence and tolerance in the mouse following chronic oral administration (2005) (88)
- Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent (2008) (87)
- Regional and cellular distribution of CYP2D subfamily members in rat brain (2000) (86)
- Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. (1999) (85)
- Genetic and environmental influences on the ratio of 3′hydroxycotinine to cotinine in plasma and urine (2009) (84)
- Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. (2007) (84)
- Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. (2001) (82)
- Variation in CYP2A6 Activity and Personalized Medicine (2017) (82)
- Non-nicotinic therapies for smoking cessation. (2007) (81)
- Risk factors for tobacco dependence in adolescent smokers (2006) (79)
- CYP2B6 and Bupropion's Smoking‐Cessation Pharmacology: The Role of Hydroxybupropion (2012) (79)
- Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5 (2006) (79)
- The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex (2013) (79)
- Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction (2010) (78)
- CYP2A6 Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers during Ad libitum Smoking (2006) (75)
- Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. (2001) (74)
- Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment (2008) (74)
- Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. (2012) (74)
- Decreasing smoking behaviour and risk through CYP2A6 inhibition. (2003) (72)
- The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients (2012) (72)
- Molecular genetics of nicotine metabolism. (2009) (71)
- Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. (2002) (71)
- The human dopamine D5 receptor gene: cloning and characterization of the 5'-flanking and promoter region. (1995) (70)
- Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors (2010) (68)
- Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice (2015) (68)
- Brain Drug-Metabolizing Cytochrome P450 Enzymes are Active In Vivo, Demonstrated by Mechanism-Based Enzyme Inhibition (2009) (67)
- Cohort Profile: The Nicotine Dependence in Teens (NDIT) Study. (2015) (67)
- CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers (2013) (67)
- Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. (2003) (66)
- A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent (2008) (65)
- Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation (2015) (65)
- Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. (2008) (64)
- CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. (2003) (63)
- Identification of Novel CYP2A6*1B Variants: The CYP2A6*1B Allele is Associated With Faster In Vivo Nicotine Metabolism (2008) (63)
- Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats (2008) (63)
- The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. (2003) (63)
- Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. (2003) (63)
- Rat brain CYP2B-enzymatic activation of chlorpyrifos to the oxon mediates cholinergic neurotoxicity. (2012) (63)
- The γ-aminobutyric acid receptor γ3 subunit gene (GABRG3) is tightly linked to the α5 subunit gene (GABRA5) on human chromosome 15q11–q13 and is transcribed in the same orientation (1995) (61)
- Cytochrome P450 2D6 enzyme neuroprotects against 1‐methyl‐4‐phenylpyridinium toxicity in SH‐SY5Y neuronal cells (2010) (61)
- Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. (2006) (60)
- Ibogaine in the treatment of heroin withdrawal. (2001) (59)
- Genetic Relationship between Schizophrenia and Nicotine Dependence (2016) (58)
- Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state (2013) (58)
- Genetic Relationship between Schizophrenia and Nicotine Dependence (2016) (58)
- Biomarkers for Smoking Cessation (2013) (57)
- Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI (2012) (57)
- Chapter 8 Ibogaine in the treatment of heroin withdrawal (2001) (57)
- Potential role of CYP2D6 in the central nervous system (2013) (57)
- Associations of CYP2A6 genotype with smoking behaviors in southern China. (2011) (56)
- Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. (2002) (56)
- INDUCTION AND RECOVERY TIME COURSE OF RAT BRAIN CYP2E1 AFTER NICOTINE TREATMENT (2006) (55)
- Drug Metabolism within the Brain Changes Drug Response: Selective Manipulation of Brain CYP2B Alters Propofol Effects (2011) (55)
- Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. (2000) (54)
- The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [11C]CURB (2015) (54)
- Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. (2003) (54)
- Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism (2010) (54)
- Altered gabaa receptor subunit and splice variant expression in rats treated with chronic intermittent ethanol. (2001) (53)
- Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. (2001) (52)
- The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race (2014) (52)
- Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk (2018) (51)
- Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine (2006) (50)
- The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. (2002) (49)
- A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo (2009) (49)
- Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African American smokers (2014) (49)
- Pharmacogenetics of nicotine and associated smoking behaviors. (2015) (49)
- Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. (2013) (49)
- Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. (2013) (49)
- Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking (2016) (48)
- Rat Hepatic CYP2E1 Is Induced by Very Low Nicotine Doses: An Investigation of Induction, Time Course, Dose Response, and Mechanism (2003) (47)
- Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. (2005) (47)
- CYP2B6 Genotype Does Not Alter Nicotine Metabolism, Plasma Levels, or Abstinence with Nicotine Replacement Therapy (2007) (47)
- Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. (2001) (46)
- CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment (2006) (46)
- Variation in Trans-3′-Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake (2013) (46)
- HUMAN CYP2D6 AND MOUSE CYP2DS: ORGAN DISTRIBUTION IN A HUMANIZED MOUSE MODEL (2005) (46)
- Mimicking Gene Defects to Treat Drug Dependence (2000) (46)
- Dopamine genes and nicotine dependence in treatment seeking and community smokers (2009) (46)
- Pharmacogenetics of Nicotine Metabolism in Twins: Methods and Procedures (2004) (46)
- CYP‐mediated drug metabolism in the brain impacts drug response (2017) (45)
- Utility and Relationships of Biomarkers of Smoking in African-American Light Smokers (2009) (44)
- Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. (2015) (44)
- Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. (2001) (44)
- A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. (1999) (44)
- Gene–gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism (2007) (43)
- Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. (2010) (43)
- Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. (1998) (43)
- Selegiline Is a Mechanism-Based Inactivator of CYP2A6 Inhibiting Nicotine Metabolism in Humans and Mice (2008) (43)
- Increases in α4* but not α3*/α6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment (2006) (43)
- CYP2A6 genetic variation and dexmedetomidine disposition (2012) (42)
- Pharmacogenetics: A Tool for Identifying Genetic Factors in Drug Dependence and Response to Treatment (2010) (42)
- Nicotine Pharmacokinetics in Rats Is Altered as a Function of Age, Impacting the Interpretation of Animal Model Data (2014) (42)
- Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB (2016) (41)
- Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies (1998) (41)
- First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo. (2013) (41)
- Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2 (2016) (41)
- CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people (2012) (41)
- Dopaminergic Signaling Mediates the Motivational Response Underlying the Opponent Process to Chronic but Not Acute Nicotine (2010) (40)
- Sex differences in tobacco withdrawal and responses to smoking reduced-nicotine cigarettes in young smokers (2017) (40)
- Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. (1997) (39)
- Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo (2014) (39)
- Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. (2013) (39)
- Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking (2015) (38)
- CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations. (2015) (37)
- Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. (2013) (37)
- Exposure to Nicotine and Carcinogens among Southwestern Alaskan Native Cigarette Smokers and Smokeless Tobacco Users (2012) (37)
- New CYP2A6 gene deletion and conversion variants in a population of Black African descent. (2010) (37)
- Factors that Explain Differences in Abstinence between Black and White Smokers: A Prospective Intervention Study. (2019) (36)
- Effect of Mailing Nicotine Patches on Tobacco Cessation Among Adult Smokers: A Randomized Clinical Trial. (2016) (36)
- PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6 (2012) (36)
- Inhibition of Nicotine Metabolism by Methoxysalen: Pharmacokinetic and Pharmacological Studies in Mice (2007) (36)
- Genome‐wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences (2018) (35)
- Cytochrome P450 2D6 and treatment of codeine dependence. (2000) (34)
- Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. (2011) (34)
- Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. (1997) (34)
- Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine (2015) (33)
- UGT1A and UGT2B Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers (2014) (32)
- Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors (2020) (32)
- Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. (2009) (31)
- Epigenome-wide association study of serum cotinine in current smokers reveals novel genetically driven loci (2019) (31)
- Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro. (1989) (31)
- CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers (2017) (31)
- Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity (2016) (31)
- Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors (2017) (31)
- Genotyping human CYP2A6 variants. (2002) (31)
- Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. (1999) (30)
- Imaging Changes in Synaptic Acetylcholine Availability in Living Human Subjects (2013) (30)
- Differential Effects of Nicotine Treatment and Ethanol Self-Administration on CYP2A6, CYP2B6 and Nicotine Pharmacokinetics in African Green Monkeys (2012) (30)
- Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate (2016) (29)
- Reduced-Nicotine Cigarettes in Young Smokers: Impact of Nicotine Metabolism on Nicotine Dose Effects (2017) (29)
- Treatment of Codeine Dependence With Inhibitors of Cytochrome P450 2D6 (2002) (29)
- Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics (2006) (29)
- Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities (2019) (29)
- CYP2A6 Genotype but not Age Determines Cotinine Half-life in Infants and Children (2013) (29)
- Pharmacogenetic Optimization of Smoking Cessation Treatment. (2017) (28)
- Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial. (2019) (28)
- Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent (2020) (28)
- Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. (2011) (28)
- RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles (2015) (27)
- Genetic Influences on Smoking: A Brief Review (2005) (27)
- Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein (2006) (26)
- Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism (2015) (26)
- Evaluating the Temporal Relationships Between Withdrawal Symptoms and Smoking Relapse (2019) (26)
- CYP2D6 and CYP2A6 biotransform dietary tyrosol into hydroxytyrosol. (2017) (26)
- Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice (2014) (26)
- High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. (2013) (25)
- Corrigendum to “Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking” [Drug Alcohol Depend. 89/1 (2007) 24–33] (2009) (25)
- A systems biology network model for genetic association studies of nicotine addiction and treatment (2009) (24)
- Ethanol self-administration and nicotine treatment induce brain levels of CYP2B6 and CYP2E1 in African green monkeys (2013) (24)
- Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. (2006) (24)
- Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms (2017) (23)
- Effect of metabolic blockade on the psychoactive effects of dextromethorphan (2010) (23)
- The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. (2016) (23)
- Differences in the rate of nicotine metabolism among smokers with and without HIV. (2019) (23)
- Nicotine‐motivated behavior in Caenorhabditis elegans requires the nicotinic acetylcholine receptor subunits acr‐5 and acr‐15 (2013) (23)
- Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research. (2007) (23)
- Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor. (2014) (22)
- Neural basis of smoking‐induced relief of craving and negative affect: Contribution of nicotine (2018) (22)
- Infusion of brain‐derived neurotrophic factor into the ventral tegmental area switches the substrates mediating ethanol motivation (2013) (22)
- CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. (2013) (22)
- Organic cation transporter variation and response to smoking cessation therapies. (2014) (22)
- In Vivo and in Vitro Characterization of Chlorzoxazone Metabolism and Hepatic CYP2E1 Levels in African Green Monkeys: Induction by Chronic Nicotine Treatment (2006) (22)
- Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data (2011) (22)
- Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence (2018) (22)
- Conversion of bromperidol to reduced bromperidol in human liver. (1991) (22)
- Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration (2015) (21)
- CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms. (2016) (21)
- Developmental Hippocampal Neuroplasticity in a Model of Nicotine Replacement Therapy during Pregnancy and Breastfeeding (2012) (21)
- Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes (2014) (21)
- Measures and predictors of varenicline adherence in the treatment of nicotine dependence. (2017) (21)
- The influence of an endogenous β3 subunit on recombinant GABAA receptor assembly and pharmacology in WSS-1 cells and transiently transfected HEK293 cells (2000) (21)
- Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. (2015) (21)
- Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways (2018) (20)
- Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment (2006) (20)
- Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors (2010) (20)
- Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer (2017) (20)
- The gamma-aminobutyric acid receptor gamma 3 subunit gene (GABRG3) is tightly linked to the alpha 5 subunit gene (GABRA5) on human chromosome 15q11-q13 and is transcribed in the same orientation. (1995) (20)
- Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption (2015) (20)
- Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males (2015) (20)
- Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [11C]-(+)-PHNO PET Study (2016) (19)
- Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6). (1992) (19)
- Tobacco use among southwestern Alaska Native people. (2013) (19)
- Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption (2014) (19)
- Neuroimaging in Psychiatric Pharmacogenetics Research: The Promise and Pitfalls (2013) (19)
- Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment? (2017) (19)
- The Role of Cytochrome P450 2C19 Activity in Flunitrazepam Metabolism In Vivo (2003) (19)
- The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings (2017) (19)
- Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers. (2016) (18)
- Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study (2020) (18)
- Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. (2018) (18)
- PharmVar GeneFocus: CYP2B6 (2021) (18)
- Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB (2020) (18)
- CYP2D6 phenotype and genotype in a Canadian Native Indian population. (1997) (18)
- Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers (2013) (17)
- Effect of food training and training dose on nicotine self-administration in rats (2014) (17)
- C57BL/6 Substrain Differences in Pharmacological Effects after Acute and Repeated Nicotine Administration (2019) (17)
- Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trial. (2016) (17)
- Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. (2015) (17)
- Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity (2020) (17)
- Using a Mobile Laboratory to Study Mental Health, Addictions and Violence: A Research Plan (2011) (17)
- Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism (2018) (16)
- Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis (2020) (16)
- Gender Stratified Gene and Gene–Treatment Interactions in Smoking Cessation (2011) (16)
- A Conditionally Immortalized Glial Cell Line that Expresses Mature Myelin Proteins and Functional GABAA Receptors (1998) (16)
- Factors Associated with Discontinuation of Bupropion and Counseling Among African American Light Smokers in a Randomized Clinical Trial (2013) (16)
- Case-control study of genotypes in multiple chemical sensitivity : CYP 2 D 6 , NAT 1 , NAT 2 , PON 1 , PON 2 and MTHFR (2004) (16)
- The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. (2013) (16)
- Independent and Combined Effects of Ethanol Self-Administration and Nicotine Treatment on Hepatic CYP2E1 in African Green Monkeys (2011) (15)
- Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol (2011) (15)
- Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans (2017) (15)
- The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. (1997) (15)
- Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers (2018) (15)
- Inducing rat brain CYP2D with nicotine increases the rate of codeine tolerance; predicting the rate of tolerance from acute analgesic response (2017) (14)
- Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry. (1990) (14)
- Pregnancy-Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During Antepartum and Postpartum. (2018) (14)
- Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. (2008) (14)
- Perceptions of pharmacogenetic research to guide tobacco cessation by patients, providers and leaders in a tribal healthcare setting. (2016) (14)
- Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users : Imaging With the Novel Radiotracer [ 11 C ] CURB (2016) (14)
- Intracerebroventricularly and systemically delivered inhibitor of brain CYP2B (C8-Xanthate), even following chlorpyrifos exposure, reduces chlorpyrifos activation and toxicity in male rats. (2014) (13)
- Designer Drugs That Are Potent Inhibitors of CYP2D6 (2002) (13)
- Genetic and Pharmacokinetic Determinants of Response to Transdermal Nicotine in White, Black and Asian Non-Smokers (2013) (13)
- Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. (2002) (13)
- A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. (2016) (13)
- Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism. (2006) (13)
- Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How (2018) (13)
- Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England (2017) (13)
- Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer (2018) (13)
- OpenVape: An Open-Source E-Cigarette Vapor Exposure Device for Rodents (2020) (13)
- “Target-Site” Drug Metabolism and Transport (2015) (13)
- The Late Positive Potentials Evoked by Cigarette-Related and Emotional Images Show no Gender Differences in Smokers (2019) (13)
- HUMAN CYP 2 D 6 AND MOUSE CYP 2 DS : ORGAN DISTRIBUTION IN A HUMANIZED MOUSE MODEL (2005) (12)
- Fatty acid amide hydrolase is lower in young cannabis users (2020) (12)
- Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. (2014) (12)
- D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction (2019) (12)
- DSM-IV, ICD-10 and FTND: Discordant Tobacco Dependence Diagnoses in Adult Smokers (2011) (12)
- Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia (2019) (12)
- Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV Implications for Treatment and Research (2018) (12)
- Sex Differences in the Association of Cigarette Craving With Insula Structure (2021) (11)
- Cigarette consumption and biomarkers of nicotine exposure during pregnancy and postpartum (2018) (11)
- Pentobarbital decreases the gamma-aminobutyric acidA receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupation. (1997) (11)
- Addressing the instability issue of dopamine during microdialysis: the determination of dopamine, serotonin, methamphetamine and its metabolites in rat brain. (2020) (11)
- Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT (2018) (11)
- Does coffee consumption impact on heaviness of smoking? (2017) (11)
- Functional Connectivity of the Raphe Nuclei: Link to Tobacco Withdrawal in Smokers (2018) (11)
- Toward Precision Medicine for Smoking Cessation: Developing a Neuroimaging-Based Classification Algorithm to Identify Smokers at Higher Risk for Relapse. (2019) (10)
- Progress in Pharmacogenomics: Bridging the Gap From Research to Practice (2014) (10)
- Rational design of novel CYP2A6 inhibitors. (2014) (10)
- Impact of menthol on oral nicotine consumption in female and male Sprague Dawley rats. (2019) (10)
- Pharmacogenomics of nicotine metabolism: novel CYP2A6 and CYP2B6 genetic variation patterns in Alaska Native and American Indian populations. (2019) (10)
- A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine (2018) (10)
- Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis (2013) (10)
- Fatty acid amide hydrolase binding is inversely correlated with amygdalar functional connectivity: a combined positron emission tomography and magnetic resonance imaging study in healthy individuals (2021) (10)
- The genetic aspects of nicotine metabolism and their impact on adolescent nicotine dependence (2010) (9)
- Association of the Fatty Acid Amide Hydrolase C385A Polymorphism with Alcohol Use Severity and Coping Motives in Heavy-drinking Youth. (2021) (9)
- Relationships Between Smoking Behaviors and Cotinine Levels Among Two American Indian Populations With Distinct Smoking Patterns (2018) (9)
- DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers (2012) (9)
- Transferability of Ancestry‐Specific and Cross‐Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations (2020) (9)
- Characterization and Comparison of Nicotine and Cotinine Metabolism in Vitro and in Vivo in DBA / 2 and C 57 BL / 6 Mice (2007) (9)
- Genome-Wide Meta-Analyses of FTND and TTFC Phenotypes. (2019) (9)
- Cytochromes P450 in the brain: Emerging evidence for biological significance (2011) (8)
- Propranolol is a mechanism‐based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6‐transgenic mice: Effects on activity and drug responses (2020) (8)
- Simultaneous determination of haloperidol and reduced haloperidol by gas chromatography using a megabore column with electron-capture detection: application to microsomal oxidation of reduced haloperidol. (1990) (8)
- Relationship Between Amounts of Daily Cigarette Consumption and Abdominal Obesity Moderated by CYP2A6 Genotypes in Chinese Male Current Smokers (2012) (8)
- Impact of Early Nausea on Varenicline Adherence and Smoking Cessation. (2019) (8)
- Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice (2020) (8)
- CYP2A6 allele frequencies in an Iranian population. (2008) (8)
- Does Menthol Cigarette Use Moderate the Effect of Nicotine Metabolism on Short-Term Smoking Cessation? (2017) (7)
- Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers (2018) (7)
- Functional connectivity of the anterior insula during withdrawal from cigarette smoking (2021) (7)
- Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes. (2018) (7)
- The documented role of pharmacogenetic: in the identification and administration of new medications for treating drug abuse. (1996) (7)
- Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real‐world settings? A prospective study (2018) (7)
- Changes in Nicotine Metabolite Ratio among Daily Smokers receiving Treatment for Alcohol Use Disorder. (2018) (7)
- Differences in the rate of nicotine metabolism among smokers with and without HIV. (2019) (7)
- Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans (2019) (7)
- The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine (2017) (7)
- Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors. (2019) (6)
- Effects of varenicline on cognitive function in non-smokers with schizophrenia (2017) (6)
- Drug Addiction: A Critical Problem Calling for Novel Solutions (2008) (6)
- Attitudes toward Precision Treatment of Smoking in the Southern Community Cohort Study (2019) (6)
- Differences in propensity for drinking alcohol are reflected in subunit‐ and region‐specific GABAA receptor levels (1999) (6)
- Inhibition of CYP2A6 decreases smoking (1999) (6)
- Brain CYP2B induction can decrease nicotine levels in the brain (2017) (6)
- Relevance of deficient CYP2D6 in opiate dependence (1998) (5)
- Beyond Quitting: Any Additional Impact of Mailing Free Nicotine Patches to Current Smokers? (2018) (5)
- The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence (2018) (5)
- The role of CYP2D in rat brain in methamphetamine-induced striatal dopamine and serotonin release and behavioral sensitization (2021) (5)
- Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers: The Kick It at Swope IV Randomized Clinical Trial. (2022) (5)
- Addiction Research Centres and the Nurturing of Creativity. Substance abuse research in a modern health care centre: the case of the Centre for Addiction and Mental Health. (2011) (4)
- Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study (2020) (4)
- Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. (2020) (4)
- Pharmacogenomics, Second Edition (2005) (4)
- Opioids: The Painful Public Health Reality (2018) (4)
- Contribution of Biotransformations Carried Out by the Microbiota, Drug-Metabolizing Enzymes, and Transport Proteins to the Biological Activities of Phytochemicals Found in the Diet. (2021) (4)
- Dose-independent kinetics with low level exposure to nicotine and cotinine. (2013) (4)
- Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. (2019) (4)
- The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers (2020) (4)
- Improvement of the association between self-reported pill count and varenicline levels following exclusion of participants with misreported pill count: A commentary on Peng et al. (2017). (2018) (4)
- Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. (2021) (4)
- Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes (2021) (4)
- Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans (2021) (4)
- The Role of Pharmacogenetics in Smoking (2021) (4)
- Heinz Lehmann Award paper Cytochrome P 450 – mediated drug metabolism in the brain (2013) (3)
- Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation (2017) (3)
- Use of electronic nicotine delivery systems (ENDS) among U.S. women of reproductive age: Prevalence, reported reasons for use, and toxin exposure. (2021) (3)
- Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance (2021) (3)
- Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV. (2020) (3)
- Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: A focus on nicotinic receptors and nicotine metabolizing enzyme (2020) (3)
- Long-term effectiveness of mailed nicotine replacement therapy: study protocol of a randomized controlled trial 5-year follow-up (2017) (3)
- Nicotine Metabolism and its Implications (2012) (3)
- Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults (2019) (3)
- Cytochrome P450 (CYP) 2A6 Genetic Variation Predicts Letrozole Plasma Concentrations in Postmenopausal Women with Breast Cancer. (2009) (3)
- The influence of smoking, alcoholism and genetics on CYP2B6 in human brain (2003) (2)
- Racial disparities in intensity of smoke exposure and nicotine intake among low-dependence smokers. (2021) (2)
- Null Results in Brief CYP 2 B 6 Genotype Does Not Alter Nicotine Metabolism , Plasma Levels , or Abstinence with Nicotine Replacement Therapy (2007) (2)
- Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone Levels (2021) (2)
- CYP2A6 Genetic Variation and Variable Nicotine Metabolism Among Two Distinct American Indian Tribal Groups With Different Levels of Smoking and Risk For Tobacco‐Related Cancer (2015) (2)
- Acute effects of a very low nicotine content cigarette on laboratory smoking lapse: Impacts of nicotine metabolism and nicotine dependence (2020) (2)
- Stability of varenicline concentration in saliva over twenty-one days at three storage temperatures. (2021) (2)
- Cytochrome P450 enzymes and metabolism of drugs and neurotoxins within the mammalian brain. (2022) (2)
- 51. Investigating Endocannabinoid Mechanisms in Posttraumatic Stress Disorder: Neuroimaging Studies With the Novel Fatty Acid Amide Hydrolase Probe, [11C]CURB (2018) (2)
- In memoriam: Werner Kalow, MD (1917–2008) (2008) (2)
- Impact Of Cyp2a6 Activity On Nicotine Reinforcement And Cue-Reactivity In Daily Smokers. (2021) (2)
- Five-Year Follow-up of a Randomized Clinical Trial Testing Mailed Nicotine Patches to Promote Tobacco Cessation. (2020) (2)
- Brief Report: Nicotine Metabolism Ratio Increases in HIV-Positive Smokers on Effective Antiretroviral Therapy: A Cohort Study (2021) (2)
- Does the GABAA Receptor Have a Role to Play in Angelman Syndrome (1996) (2)
- Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice (2020) (2)
- Centrally administered CYP2D inhibitors increase oral tramadol analgesia in rats (2020) (2)
- Effects of Nicotine Metabolic Rate on Cigarette Reinforcement. (2019) (2)
- Nicotine Kinetics in Zebra Finches In Vivo and In Vitro (2013) (2)
- Rational design of novel CYP2A6 inhibitors (2013) (1)
- Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia. (2022) (1)
- Lymphoma-Associated Biomarkers Are Increased in Current Smokers in Twin Pairs Discordant for Smoking (2021) (1)
- A Physiological Marriage Made in Heaven: Treating and Measuring the Brain Through Stimulation (2019) (1)
- 619. Brain Levels of Fatty Acid Amide Hydrolase Are Not Altered in Overweight Healthy Individuals: A Pilot PET Study with [11C]CURB (2017) (1)
- 12 Using Ontologies in Hierarchical Modeling of Genes and Exposure in Biological Pathways (2017) (1)
- Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe (2022) (1)
- S265. Endocannabinoid Metabolism and Alcohol Consumption in Youth: A PET Study With the Fatty Acid Amide Hydrolase Radioligand [11C]CURB (2018) (1)
- Evaluation of nicotine patch adherence measurement using self-report and saliva cotinine among abstainers in a smoking cessation trial. (2020) (1)
- The Effect of Tobacco Use on the Expression of Placental Transporters in Alaska Native Women (2022) (1)
- Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving. (2022) (1)
- FLUNITRAZEPAM METABOLISM BY CYTOCHROME P 450 S 2 C 19 AND 3 A 4 (2001) (1)
- An A-Z Guide to Pharmacogenomics. (2007) (1)
- CYP2A6 genotype and toxicity of nicotine in never smokers (2005) (1)
- Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration, and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis. (2021) (1)
- in a population of Black African descent (2010) (1)
- A genome-wide association study of nausea incidence in varenicline-treated cigarette smokers. (2021) (1)
- Impact of self-reported lifetime depression or anxiety on effectiveness of mass distribution of nicotine patches (2016) (1)
- T76. Involvement of the Endocannabinoid Enzyme Fatty Acid Amide Hydrolase in the Neurobiology of Impulsivity: Positron Emission Tomography Studies With [11C]CURB (2018) (1)
- Brain and Disease: The Long Path to Discovery and Treatment (2009) (1)
- The Influence of Tobacco Smoke/Nicotine on CYP2A Expression in Human and African Green Monkey Lungs (2020) (1)
- Does genetic variation in a bitter taste receptor gene alter early smoking behaviors in adolescents and young adults? (2022) (1)
- Title : Predictors of variation in CYP 2 A 6 mRNA , protein , and enzyme activity in a human liver bank : influence of genetic and non-genetic factors (2016) (1)
- Concentrated Distribution of Nicotine Patches to a Town With High Smoking Rates—Any Evidence of Large Impacts on Tobacco Cessation? (2022) (0)
- Nicotine plasma levels in adult male ICR mouse after pre-treatment with vehicle or menthol in the withdrawal testing. (2015) (0)
- Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England (2017) (0)
- Examining the role of mitochondrial genetic variation in nicotine dependence (2022) (0)
- CYP2A6 genetic variation and dexmedetomidine disposition (2012) (0)
- Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy (2023) (0)
- 346. Endocannabinoid Metabolism Linked With Alcohol Use in Individuals With Social Anxiety Disorder: A Positron Emission Tomography Study With [11C]CURB (2023) (0)
- Genetic Relationship between Schizophrenia and Nicotine Dependence (2016) (0)
- biosamples in smoking cessation trials: a genetic, and epigenetic (2017) (0)
- In vivo brain endocannabinoid metabolism is related to hippocampus glutamate and structure – a multimodal imaging study with PET, 1H-MRS, and MRI (2022) (0)
- CYP 2 A 6 genetic variation alters striatal-cingulate circuits , network hubs and executive processing in smokers CYP 2 A 6 and striatal-cingulate circuit in smokers (2016) (0)
- 386. Fatty Acid Amide Hydrolase is Associated With Impulsiveness: A Pet Study in Overnight Abstinent Chronic Cannabis Users (2023) (0)
- P648. Fatty Acid Amide Hydrolase and Threat Related Amygdala Activity in Individuals With PTSD (2022) (0)
- P13. Dissecting the Association of CYP2A6 With Nicotine Metabolism in African American Smokers (2022) (0)
- Role of CYP 2 A 6 Genet ic Variat ion on Smoking Behaviors and Cl inica l Impl icat ions (2008) (0)
- Investigating Fatty Acid Amide Hydrolase Levels in Social Anxiety Disorder: A Positron Emission Tomography (PET) Study Using [C-11]CURB (2020) (0)
- Hydroxytyrosol formation from Tyrosol and its effects on the cardiovascular system; results from a randomized controlled clinical trial (2022) (0)
- Epigenome-wide association study of serum cotinine in current smokers reveals novel genetically driven loci (2019) (0)
- The Late Positive Potentials Evoked by Cigarette-Related and Emotional Images Show no Gender Differences in Smokers (2019) (0)
- Pentobarbital Decreases the g-Aminobutyric AcidA Receptor Subunit gamma-2 Long / Short mRNA Ratio by a Mechanism Distinct from Receptor Occupation 1 (1997) (0)
- S203. Fatty Acid Amide Hydrolase Polymorphism C385A Associated With Dopamine D2/3 Receptor Levels: A PET Study With [11C]-(+)-PHNO (2019) (0)
- Genotyping, characterization, and imputation of known and novel CYP2A6 structural variants using SNP array data. (2023) (0)
- Correction to: Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C] CURB positron emission tomography study (2021) (0)
- Blockade of menthol’s effects on nicotine acute pharmacological responses after administration in mice. (2015) (0)
- Cytochrome p45 0IID6 (debrisoquine hydroxylase): inhibition studies in liver and brain (1990) (0)
- OF 18-METHOXYCORONARIDINE , AN IBOGAINE ANALOG , TO 18-HYDROXYCORONARIDINE BY GENETICALLY VARIABLE CYP 2 C 19 (2002) (0)
- Sex differences in brain oxycodone metabolism and analgesia (2019) (0)
- Effect of hepatic nicotine metabolism on nicotinic acetylcholine receptor availability and craving (2014) (0)
- Modifying the Metabolism of Nicotine as a Therapeutic Strategy (2008) (0)
- Sex differences in tobacco withdrawal and responses to smoking reduced-nicotine cigarettes in young smokers (2017) (0)
- Gene Variants in CYP 2 C 19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes s (2014) (0)
- Effects of menthol on nicotine withdrawal signs. (A) Elevated plus-maze test, (B) Somatic signs and in (C) Hyperalgesia. (2015) (0)
- Pharmacogenetics and Smoking Cessation (2019) (0)
- and its possible pathways (2011) (0)
- Effect of a nicotine vaccine on nicotine binding to the beta2-nAChRs in vivo in human tobacco smokers (2013) (0)
- Different measures of varenicline adherence, nicotine metabolite ratio and smoking abstinence (2019) (0)
- Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke (2021) (0)
- Use of additional nicotine replacement therapy by participants in a five-year follow-up of a tobacco cessation trial. (2021) (0)
- Abstract 4149: Genetic variation in CYP2A6, a nicotine/nitrosamine metabolism enzyme, influences lung cancer risk in two independent case-control studies of African American smokers (2014) (0)
- S.05.03 CYP2D activity in the brain acts independently from CYP2D in the liver to alter CNS drug levels and response (2016) (0)
- Humanized CYP2C19 transgenic mouse as an animal model of cerebellar ataxia (2022) (0)
- Nicotine dependence and functional connectivity of insular cortex subregions (2021) (0)
- Endocannabinoid Metabolism in Posttraumatic Stress Disorder: Results From a Neuroimaging Study With the Novel Fatty Acid Amide Hydrolase Probe, [C-11] Curb (2020) (0)
- 2 Humans 2 . 1 Human Nicotine Metabolism (2009) (0)
- The impact of nicotine metabolite ratio on pharmacotherapy effectiveness in real-world settings: a longitudinal analysis (2018) (0)
- Nicotine metabolite ratio in plasma and urine by different analytical methods and laboratories: Implications for clinical implementation (2015) (0)
- Personalized dosing of nicotine replacement therapy versus standard dosing for the treatment of individuals with tobacco dependence: study protocol for a randomized placebo-controlled trial (2020) (0)
- Inhibitor combinations CYP2A enzyme and nicotine and its therapeutic utilizon. (1998) (0)
- Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence (2022) (0)
- A mouse model for investigating human brain CYP2D6 (2019) (0)
- Abstract 3228: Tobacco smoking and circulating immune-related biomarkers in monozygotic twins (2018) (0)
- Contributors (2019) (0)
- TITLE: INTRACEREBROVENTRICULARLY AND SYSTEMICALLY DELIVERED INHIBITOR OF BRAIN CYP2B (C8-XANTHATE), EVEN FOLLOWING CHLORPYRIFOS EXPOSURE, REDUCES CHLORPYRIFOS ACTIVATION AND TOXICITY IN MALE RATS RUNNING TITLE: CYP2B INHIBITOR REDUCES CHLORPYRIFOS TOXICITY (2014) (0)
- Time course of nicotine plasma concentrations in mice pretreated with menthol. (2015) (0)
- Genetic variation in fatty acid amide hydrolase (FAAH): Associations with early drinking and smoking behaviors. (2022) (0)
- DMD058719 1447..1455 (2014) (0)
- Offering nicotine patches to all households in a community with high smoking rates: Pilot test of a population-based approach to promote tobacco cessation (2021) (0)
- Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors (2020) (0)
- Brief Report: HIV Infection Does Not Explain Higher Nicotine Metabolism in People Living With HIV (2022) (0)
- The use of biomarkers to guide precision treatment for tobacco use. (2023) (0)
- Genetics of Smoking Behaviors in American Indians (2020) (0)
- The Brain as a Drug Metabolizing Organ: Genetic Variability in CNS Opiate Metabolism. (1995) (0)
- Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes (2022) (0)
- Effects of menthol pretreatment on nicotine-induced antinociception and hypothermia dose-response curves in mice. (2015) (0)
- Association between Fatty Acid Amide Hydrolase and Alcohol Response Phenotypes: A PET Imaging Study with [11C]CURB in Heavy-drinking Youth (2022) (0)
- A pilot randomized controlled trial of precision care for smoking cessation in the Southern CommunityCohort Study (2020) (0)
- Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk (2018) (0)
- P.1.g.042 Haloperidol-induced catalepsy, a model of acute antipsychotic-induced extrapyramidal side effects, is altered by inhibiting and inducing CYP2D in rat brain (2016) (0)
- Alcoholism, smoking and cyp-mediated drug metabolism (2006) (0)
- NICOTINE INDUCED INCREASES IN NEURAL INHIBITION AS A MECHANISM FOR ACUTE SYMPTOM ATTENUATION AMONG PATIENTS WITH SCHIZOPHRENIA (2008) (0)
- 706 Ethnic variation in CYP2A6: impact on smoking and health consequences (2000) (0)
- Socioeconomic and drug use determinants of smoking status in a Canadian urban adult population of black African descent (2018) (0)
- Nicotine metabolite ratio and associations with smoking topography in a population with affective disorders (2017) (0)
- Effects of Nicotine Metabolic Rate on withdrawal symptoms and response to cigarette smoking following abstinence (2018) (0)
- 4199 A pilot randomized controlled trial of precision care for smoking cessation in the Southern Community Cohort Study (2020) (0)
- RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles (2015) (0)
- Nicotine dependence and insula subregions: functional connectivity and cue-induced activation (2023) (0)
- The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia (2022) (0)
- Comparing the Rate of Nicotine Metabolism Among Smokers With Current or Past Major Depressive Disorder. (2021) (0)
- Sparteine monooxygenase in brain and liver: Identified by the dopamine uptake blocker ( sup 3 H)GBR-12935 (1990) (0)
- Changes in nicotine metabolic pathways across pregnancy: A longitudinal study (2018) (0)
- Dispositional optimism and optimistic bias: Associations with cessation motivation, confidence, and attitudes. (2022) (0)
- Fatty Acid Amide Hydrolase and Threat Related Amygdala Activity: A Combined Positron Emission Tomography and Magnetic Resonance Imaging Study (2020) (0)
- Impact of menthol treatment on nicotine pharmacokinetic parameters. (2015) (0)
- CYP2D in the brain impacts oral hydrocodone analgesia in vivo (2022) (0)
- The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race (2014) (0)
- Influence of CYP2A6 genetic variation, nicotine dependence severity, and treatment on smoking cessation success. (2023) (0)
- Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice (2020) (0)
This paper list is powered by the following services:
Other Resources About Rachel Tyndale
What Schools Are Affiliated With Rachel Tyndale?
Rachel Tyndale is affiliated with the following schools:
